- Foundayo (orforglipron) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition
- It is the first oral small-molecule GLP-1 — a once-daily pill with no food or water restrictions
- PEAK Wellness is now prescribing Foundayo at our Chesapeake, VA clinic
- Eli Lilly’s savings card can bring costs as low as $25/month for eligible patients
What is Foundayo?
Foundayo (orforglipron) is a once-daily oral tablet manufactured by Eli Lilly. It was FDA-approved in April 2026 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related condition. It is a GLP-1 receptor agonist — the same drug class as Wegovy and Zepbound — but as a small-molecule compound rather than a peptide, it can be taken as a simple pill.
The key differentiator: no food or water restrictions. Unlike the Wegovy Pill (oral semaglutide), which must be taken on an empty stomach with limited water and a 30-minute wait before eating, Foundayo can be taken any time of day with or without food.
In the ATTAIN-1 clinical trial, patients taking the 17.2 mg dose lost approximately 11% of their body weight over 72 weeks.
Why this matters for patients
Until now, the most effective GLP-1 weight loss medications required weekly injections. Some patients have avoided treatment entirely because of needle anxiety or the inconvenience of injection schedules. Others have been interested in oral options but found the strict dosing rules of the Wegovy Pill — empty stomach, limited water, 30-minute fasting window — difficult to maintain.
Foundayo adds a genuinely new option: effective GLP-1 treatment in a daily pill with no dosing restrictions. For patients who want the benefits of a GLP-1 without injections — and without the strict empty-stomach rules of the Wegovy Pill — this is a meaningful step forward.
For patients who have been waiting for an effective oral option without injection or dosing restrictions, Foundayo is exactly that.
How to get started at PEAK
Schedule a consultation to discuss whether Foundayo is right for you. Our providers evaluate your health history, current medications, and goals to recommend the best FDA-approved option.
PEAK accepts Anthem, Cigna, Aetna, UnitedHealthcare, Sentara, and TRICARE. We do not accept Medicare or Medicaid. Initial provider visit is $199 self-pay, follow-up visits are $135, and dietitian visits are $75. Insurance verification is handled before your first visit.
Eli Lilly’s savings card may reduce Foundayo costs to as low as $25/month for commercially insured patients. Self-pay through LillyDirect ranges from $149–$299/month depending on dose. See our Foundayo savings card guide for details on eligibility and how to apply.
Common questions
Yes, we are now prescribing Foundayo for eligible patients. Schedule a consultation to discuss whether it’s right for you.
Not necessarily. Your provider will evaluate whether Foundayo is appropriate based on your health profile, current treatment, and goals. Medication changes should always be made under medical supervision.
Coverage is still being established by most insurance plans. Eli Lilly offers a savings card that can bring costs as low as $25/month for patients with eligible commercial insurance. For those without coverage, LillyDirect self-pay pricing ranges from $149–$299/month. See our Foundayo savings card page for full details.
No. Foundayo is a different drug (orforglipron) from a different manufacturer (Eli Lilly). It targets the GLP-1 receptor like Wegovy but is a small-molecule compound, not a peptide. In clinical trials, it produced approximately 11% weight loss vs approximately 15% for Wegovy and approximately 22% for Zepbound. See our Foundayo vs Zepbound and Foundayo vs Wegovy Pill comparison pages for details.
The most common side effects are GI-related: nausea, diarrhea, and constipation. These tend to improve with gradual dose titration. Foundayo carries a boxed warning about thyroid C-cell tumors based on findings with other GLP-1 receptor agonists in rodent studies; orforglipron itself did not produce thyroid C-cell tumors in animal studies. See the full safety information on our Foundayo treatment page.
Important safety information: Foundayo (orforglipron) carries a boxed warning about thyroid C-cell tumors (medullary thyroid carcinoma) based on findings with other GLP-1 receptor agonists in rodent studies. Orforglipron itself did not produce thyroid C-cell tumors in animal studies. Foundayo is contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Common side effects include nausea, diarrhea, vomiting, and constipation. Discuss your full medical history with your clinician before starting treatment.
